Suppr超能文献

生长激素释放激素与生长激素释放肽-6联合给药后活动性肢端肥大症患者的生长激素(GH)分泌

Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6.

作者信息

Popovic V, Damjanovic S, Micic D, Petakov M, Dieguez C, Casanueva F F

机构信息

Institute of Endocrinology, University Clinical Center, Belgrade, Yugoslavia.

出版信息

J Clin Endocrinol Metab. 1994 Aug;79(2):456-60. doi: 10.1210/jcem.79.2.8045963.

Abstract

His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (called GHRP-6) is a synthetic compound that releases GH in a dose-related, specific, and nonspecies-specific manner, through mechanisms different from those of GHRH. Being, normally, more potent than GHRH, GHRP-6 shows a striking synergistic action when administered simultaneously with GHRH, although the mechanisms and point of action of such a potentiating effect are unknown. The aim of the present study was 2-fold: 1) to further characterize the actions and mechanisms of GHRP-6 as well as its synergistic effects, and 2) to study its actions in acromegalic patients. Eleven acromegalic patients and 12 normal subjects, age and sex matched as controls, underwent 3 tests each on separate occasions, being challenged with GHRH (100 micrograms, iv), GHRP-6 (90 micrograms, iv), or GHRH plus GHRP-6. GH was analyzed as the area under the curve (mean +/- SE; micrograms per L/120 min). In normal subjects, GH secretion was 686 +/- 227 after GHRH, 1787 +/- 510 after GHRP-6, and 4111 +/- 671 after GHRH plus GHRP-6; the level of GH secreted after GHRH plus GHRP-6 treatment was significantly (P < 0.05) higher than the arithmetic sum of GH levels after both compounds administered separately. In acromegalic patients, the level of GH secreted after GHRH was 1468 +/- 499, that after GHRP-6 was 2595 +/- 762, and that after GHRH plus GHRP-6 was 4949 +/- 1043; this last value was not significantly different from the arithmetical addition of levels produced by both compounds administered separately. These results indicate that GH-secreting pituitary adenomas respond surprisingly well to either GHRH or GHRP-6 despite being deprived for long periods (even years) of the physiological regulation exerted by the hypothalamus. In addition, the synergistic action of GHRH plus GHRP-6 was observed in normal subjects, but not in acromegalic patients. These results suggest that GHRP-6 does not need to operate through hypothalamic factors to exert its GH-releasing action, even for eliciting a greater response than GHRH. On the other hand, the synergistic effect of GHRH plus GHRP-6 appears to need the cooperation of the hypothalamus, but how this occurs is still undetermined.

摘要

组氨酸-右旋色氨酸-丙氨酸-右旋色氨酸-右旋苯丙氨酸-赖氨酸-氨基(称为生长激素释放肽-6,GHRP-6)是一种合成化合物,它通过与生长激素释放激素(GHRH)不同的机制,以剂量相关、特异性且非物种特异性的方式释放生长激素(GH)。通常,GHRP-6比GHRH更有效,当与GHRH同时给药时,GHRP-6显示出显著的协同作用,尽管这种增强作用的机制和作用点尚不清楚。本研究的目的有两个:1)进一步表征GHRP-6的作用和机制及其协同效应,2)研究其在肢端肥大症患者中的作用。11例肢端肥大症患者和12例年龄和性别匹配作为对照的正常受试者,在不同时间分别接受3次测试,分别用GHRH(100微克,静脉注射)、GHRP-6(90微克,静脉注射)或GHRH加GHRP-6进行挑战。GH以曲线下面积(平均值±标准误;微克每升/120分钟)进行分析。在正常受试者中,GHRH后GH分泌为686±227,GHRP-6后为1787±510,GHRH加GHRP-后为4111±671;GHRH加GHRP-6治疗后分泌的GH水平显著高于两种化合物单独给药后GH水平的算术和(P<0.05)。在肢端肥大症患者中,GHRH后分泌的GH水平为1468±499,GHRP-6后为2595±762,GHRH加GHRP-6后为4949±1043;最后这个值与两种化合物单独给药产生的水平的算术相加无显著差异。这些结果表明,分泌GH的垂体腺瘤尽管长期(甚至数年)缺乏下丘脑施加的生理调节,但对GHRH或GHRP-6的反应出人意料地良好。此外,在正常受试者中观察到GHRH加GHRP-6的协同作用,但在肢端肥大症患者中未观察到。这些结果表明,GHRP-6发挥其GH释放作用不需要通过下丘脑因子,即使要引发比GHRH更大的反应也不需要。另一方面,GHRH加GHRP-6的协同效应似乎需要下丘脑的协同作用,但具体如何发生仍未确定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验